The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Integrated genomic analysis of EGFR-mutant non-small cell lung cancer immediately following erlotinib initiation in patients.
Trever Grant Bivona
No relevant relationships to disclose
Petros Giannikopoulos
No relevant relationships to disclose
Carlota Costa
No relevant relationships to disclose
Niki Karachaliou
No relevant relationships to disclose
Santiago Viteri
No relevant relationships to disclose
M. Rosario Garcia-Campelo
No relevant relationships to disclose
John St. John
No relevant relationships to disclose
Andrew V. Uzilov
No relevant relationships to disclose
Anne S. Wellde
No relevant relationships to disclose
William Reilly Polkinghorn
No relevant relationships to disclose
Margarita Majem
No relevant relationships to disclose
Enriqueta Felip
No relevant relationships to disclose
Enric Carcereny
No relevant relationships to disclose
Cordula Nicole Heidecke
No relevant relationships to disclose
Bartomeu Massuti
No relevant relationships to disclose
George W. Wellde
No relevant relationships to disclose
Jonathan S. Weissman
No relevant relationships to disclose
Rafael Rosell
No relevant relationships to disclose